Drug intelligence / Profile preview

NTI-XXX

Development stage: Preclinical
Lead developer: Nammi Therapeutics
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes

Overview

NTI-XXX is an investigational drug candidate developed by Nammi Therapeutics. It is currently in preclinical development, with its primary therapeutic area being neoplasms, specifically for the treatment of solid tumors. Detailed information about its mechanism of action, molecular target(s), modality, or chemical structure has not been disclosed publicly as of the latest available update (March 2025). The drug has not yet entered clinical trials and there are no records of regulatory approval or marketed products under this name[1][2].

Other names: NTI-XXX

Targets

IFNAR (Immune system modulation via type I interferon receptor)SDC1 (Syndecan-1)

Beyond the preview

Go deeper on NTI-XXX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NTI-XXX.

Explore the full profile